TB-500
Also known as: Thymosin Beta-4 fragment
Synthetic fragment of thymosin β4 studied in animal models for cell migration, angiogenesis and tissue repair. No approved human indication.

Indirect preclinical evidence
TB-500 claims mostly rely on thymosin beta-4 repair biology and preclinical data rather than direct human TB-500 outcome trials.
Mostly animal, ex vivo, cell, or indirect evidence.
Evidence basis
- Thymosin beta-4 repair biology
- Preclinical repair literature
- Weak direct human TB-500 evidence
Key references
How to read this entry
Dose references and half-life values are pulled from trial protocols, labels, reviews, or published summaries where available. They are context for research and comparison, not a personal dosing recommendation.
Status matters: approved drugs have regulated indications; investigational compounds are still being studied; research-only peptides do not have established human dosing, safety, or efficacy for consumer use.
TB-500 guides
Read the matching guide or adjacent research pages for more context.
Compare with related peptides
Stay inside the same research category and compare mechanism, status and evidence quality.
Category hub
Open the category page for the full comparison table and FAQ.